---
title: "daratumumab"
slug: "daratumumab"
date: "2024-02-20"
enableToc: false
tags:
  - building
---

> [!info]
>
> ğŸŒ± ä¾†è‡ªï¼š[[treatment of amyloidosis]]

# daratumumab

- CD38 è›‹ç™½çµåˆçš„ IgG1Îº äººé¡å–®æ ªæŠ—é«”(mAb)
- [Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis | NEJM](https://www-nejm-org.autorpa.kfsyscc.org/doi/full/10.1056/NEJMoa2028631)

> ä»–çš„ä¸­æ–‡å¾ˆå¦™ï¼šå…†ç§‘

[[daratumumab å¥ä¿è¦ç¯„.md|Daratumumab å¥ä¿è¦ç¯„]]

- Among patients with newly diagnosed AL amyloidosis, the addition of daratumumab to bortezomib, cyclophosphamide, and dexamethasone was associated with higher frequencies of hematologic complete response and survival free from major organ deterioration or hematologic progression.
- åœ¨æ–°è¨ºæ–·çš„ â†’ AL æ¾±ç²‰æ¨£è®Šæ€§æ‚£è€…ä¸­ï¼Œåœ¨ç¡¼æ›¿ä½ç±³ã€ç’°ç£·é†¯èƒºå’Œåœ°å¡ç±³æ¾çš„ â†’ åŸºç¤ä¸ŠåŠ ç”¨ daratumumab èˆ‡æ›´é«˜çš„ â†’ è¡€æ¶²å­¸å®Œå…¨ç·©è§£é »ç‡å’Œ âœ– ç„¡ä¸»è¦å™¨å®˜æƒ¡åŒ–æˆ–è¡€æ¶²å­¸é€²å±•çš„ â†’ ç”Ÿå­˜ç‡ç›¸é—œã€‚

- Mechanism:
  - Binds to **CD38**
- Dosing: 16 mg/kg IV, dosing interval varies from once weekly to every 4 wks
- PK/PD: T1/2 âˆ¼18 d
- AEs:
  - Fatigue,
  - lymphocytopenia,
  - neutropenia,
  - thrombocytopenia,
  - infusion rxn,
  - fever,
  - upper respiratory sxs,
  - herpes zoster
- DDI:
  - No known pathways of metabolism
- Clinical pearls:
  - Requires premedications before & after the infusion,
  - antiviral ppx should be started w/in 1 wk of tx & continued for 3 mos post tx,
  - interferes w/ RBC antibody screening & cross-matching
